Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Machine learning to identify CLL patients at high risk of infection

Carsten Niemann • 9 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Acalabrutinib Venetoclax

Carsten Niemann, MD, PhD, of Copenhagen University Hospital, Copenhagen, Denmark, outlines how machine learning based on data from the Danish CLL Registry can be used to identify newly diagnosed chronic lymphocytic leukemia (CLL) patients at high risk of infection. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
Paper: https://www.nature.com/articles/s41467-019-14225-8

More from Carsten Niemann

Second-line treatment in CLL after venetoclax-based frontline: insights from GAIA/CLL13 and CLL17 5:20
Second-line treatment in CLL after venetoclax-based frontline: insights from GAIA/CLL13 and CLL17
Carsten Niemann • 5 Dec 2025
Preventing infectious complications in patients with CLL: vaccination and social behaviors 3:43
Preventing infectious complications in patients with CLL: vaccination and social behaviors
Carsten Niemann • 5 Dec 2025
Data-driven hematology: next steps in the implementation of the CLL treatment infection model 3:30
Data-driven hematology: next steps in the implementation of the CLL treatment infection model
Carsten Niemann • 5 Dec 2025
The PreVent-ACaLL trial: treating patients with CLL who are at high risk of infections 2:55
The PreVent-ACaLL trial: treating patients with CLL who are at high risk of infections
Carsten Niemann • 7 Dec 2024

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals